Is natalizumab a safe treatment for patients with multiple sclerosis in the COVID-19 pandemic? Data from the first year of the pandemic

BACKGROUND: Patients with MS have increased risk of infections, especially those with highly active treatments. We studied the safety of natalizumab in patients with MS during the COVID-19 pandemic. METHODS: Demographic features, time on natalizumab, dose interval and COVID-19 symptoms were evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz-Díaz, Judit, Ramirez, Clara Isabel, Ortiz-Pica, Marta, García-Yusta, Elena, Gómez-Estevez, Irene, Oreja-Guevara, Celia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2021
Materias:
Topic: Management of MS during the COVID-19 pandemic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250634/
http://dx.doi.org/10.1016/j.msard.2021.102994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250634/
http://dx.doi.org/10.1016/j.msard.2021.102994

Ejemplares similares